Cancer therapies have transformed survival but introduced new cardiovascular risks, making Cardio-Oncology essential for modern care. This session examines how chemotherapy, targeted agents, immunotherapies, and radiation can cause cardiomyopathy, ischemia, arrhythmias, hypertension, and thromboembolism. Participants will learn to recognize early warning signs, interpret biomarkers and imaging, and distinguish reversible dysfunction from permanent injury. The aim is to protect cardiac health without compromising the efficacy of life-saving cancer treatments.

Oncologists and cardiologists increasingly look for a cardiology conference to develop shared protocols and clinics. This session reviews pre-treatment risk assessment, including history, examination, baseline echocardiography, and biomarkers such as troponin and natriuretic peptides. Attendees will explore surveillance schedules tailored to different regimens (anthracyclines, HER2-targeted therapies, VEGF inhibitors, checkpoint inhibitors) and how to respond to early changes in function or symptoms. Case-based discussions highlight complex decisions, such as whether to pause therapy, adjust doses, or continue with cardioprotective strategies.

A central theme is managing cancer therapy–related cardiac dysfunction across the continuum of oncology care. Participants will examine heart failure regimens adapted to oncology patients, including ACE inhibitors, beta-blockers, ARNI, and SGLT2 inhibitors where appropriate. The session covers management of hypertension, QT prolongation, thromboembolic risk, and radiation-induced coronary or valvular disease. Emphasis is placed on close communication among cardio-oncology team members and on documenting shared decisions with patients who may face difficult trade-offs between cancer control and cardiac safety.

The session also explores survivorship and long-term follow-up for cancer survivors at elevated cardiovascular risk. Attendees will learn how to integrate lifestyle interventions, long-term screening, and transition plans from oncology-dominated care to primary and cardiovascular follow-up. By the end, participants will be better prepared to design cardio-oncology pathways that reduce treatment interruptions, preserve cardiac function, and support the growing population of cancer survivors.